Briggs Morrison - 05 Jun 2025 Form 3/A - Amendment Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: Director
Issuer ticker: CRSP
Reported as of: 05 Jun 2025
Net transaction value: $0
SEC form: 3/A - Amendment
Accepted by SEC: 10 Jun 2025, 17:31:03 UTC
Original report date: 06 Jun 2025
Prior SEC filing: 27 Jun 2024
Next SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

Briggs Morrison filed Form 3/A - Amendment for CRISPR Therapeutics AG (CRSP) on 10 Jun 2025.

Key facts

This page summarizes Briggs Morrison's Form 3/A - Amendment filing for CRISPR Therapeutics AG (CRSP).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2025, 17:31.

Change

Previous filing in this sequence was filed on 27 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001654430 Primary reporting owner

Morrison Briggs

Relationship: Director
Address: C/O CRIPSR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Signature date: 10 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRSP holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,209
Date: 05 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 05 Jun 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 26,000
Exercise price: $48.68
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Form 3 filed on June 6, 2025 for the Reporting Person reported an incorrect number of shares held by the Reporting Person as of June 5, 2025. This amended Form 3 is being filed to correct such number of shares held by the Reporting Person as of June 5, 2025.

Footnote F2

This option was granted on December 10, 2024 with respect to 26,000 Common Shares. 100% of the shares will vest in 36 equal monthly installments, with the first vesting date of January 10, 2025.

SEC remarks

This amendment is being filed solely to correct the reporting of ownership of certain Common Shares reported in Table I. See Footnote 1 hereto.